
Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
1,000-mile Saharan dust storm, from the sky and from the ground - 2
This Huge Ocean Beast Shifts Sharks’ Evolutionary Timeline - 3
The most effective method to Remain Ahead in the Most recent Advanced Patterns with a Web based Advertising Degree - 4
Merz postpones Norway trip for Belgium talks on frozen Russian assets - 5
Would you ever turn to AI for companionship? 6% of Americans say they could — or already have.
Finding the Universe of Computer generated Reality: Individual Encounters
Europe must reinvent warfare for ‘era of shocks,’ NATO’s Vandier says
Should you get an RSV vaccine this fall? What to know and where to get a shot
Nick Reiner's defense attorney asks to be replaced, again delaying arraignment in connection with the stabbing deaths of his parents, Rob Reiner and Michele Singer Reiner
Lily Allen 2026 'West End Girl' arena tour: How to get tickets, prices and more
How to see the Ursids, the final meteor shower of 2025
This St Nick Truly Can Advise How To Drink And Hack Your Headache
Ergonomic Office Seats for Work spaces
Meet the Stars of the Feline World: Well known Pet Feline Varieties











